© 2020 HealthCore Inc.
menu
search
menu
search
keyboard_backspace All Presentations

Economic Burden of Acute Steroid-Refractory Graft Versus Host Disease (GVHD) in Commercially Insured Pediatric Patients

November 2020

[D23] Economic Burden of Acute Steroid-Refractory Graft Versus Host Disease (GVHD) in Commercially Insured Pediatric Patients

AMCP Annual Meeting 2020/AMCP eLearning DAYS

Dr. Michael Grabner, Principal Scientist for HealthCore, presents a poster entitled, “Economic Burden of Acute Steroid-Refractory Graft Versus Host Disease (GVHD) in Commercially Insured Pediatric Patients” at AMCP Annual Meeting 2020/AMCP eLearning DAYS.

This presentation reports findings from one of the first studies that estimated cost burden associated with SR aGVHD following stem cell transplants. The study used administrative claims from a large national US payor between 2006 and 2019. A total of 38 patients with SR aGVHD and 184 controls were included (mean age ~8 years, ~50% female in both cohorts). Over 12 months follow-up, the SR aGVHD cohort more frequently experienced complications (e.g. GI manifestations 95% vs. 65%) and hospital readmissions (89% vs 60%), contributing to higher direct medical costs ($1.2m vs $670k).

PRESENTER(S)
Michael Grabner, PhD
Principal Scientist